Sun Pharma Buys Organon for $12B to Expand Global Reach

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorVihaan Mehta|Published at:
Sun Pharma Buys Organon for $12B to Expand Global Reach
Overview

Sun Pharma is acquiring Organon for $12 billion in an all-cash deal, aiming to vastly expand its global reach to over 140 countries. The acquisition will strengthen its portfolio with women's healthcare and biosimilars. Motilal Oswal reiterates a BUY rating with a ₹2,025 target price, citing portfolio diversification and global presence.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • ✓Quarterly Results
  • ✓Concall Announcements
  • ✓New Orders & Big Deals
  • ✓Capex Announcements
  • ✓Bulk Deals
  • ✦And much more
Add StocksGet it on Google PlayDownload on the App Store

Sun Pharma Clinches Landmark $12 Billion Acquisition

Sun Pharmaceutical Industries Ltd. has announced a major strategic move to acquire New Jersey-based Organon for USD 12 billion in an all-cash transaction. This move is set to significantly reshape Sun Pharma's global presence and product offerings.

Portfolio Expansion and Market Reach

The acquisition will provide key advantages, including a broader product portfolio and deeper connections with healthcare professionals (HCPs). It will introduce a dedicated women's healthcare segment and strengthen Sun Pharma's existing biosimilar capabilities. The deal also significantly expands the company's commercial reach to over 140 countries worldwide.

Strengthened Global Positioning

The expansion focuses on key international markets such as the United States, European Union, China, Canada, and Brazil. Motilal Oswal analysts noted the transaction enhances Sun Pharma's global position and diversifies its portfolio. The firm reiterated its 'BUY' rating with a target price of ₹2,025, based on about 32 times 12-month forward earnings.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Add Stocks
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.